Drug intelligence / Profile preview

ND-420

Development stage: Phase 2
Lead developer: Nang Kuang Pharmaceutical
Modality: Small Molecules
Administration: Intravenous

Overview

ND-420 is a small molecule drug that was initially developed by Nang Kuang Pharmaceutical. It reached Phase 2 clinical trials for the treatment of neoplasms, specifically esophageal squamous cell carcinoma, and other digestive system disorders. The drug was investigated as part of an induction chemotherapy regimen in combination with cisplatin and fluorouracil for patients with localized squamous cell carcinoma of the esophagus. Its development has since been discontinued, and there is no publicly available information on its specific molecular target or mechanism of action[1].

Other names: Liposomal docetaxel

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on ND-420.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ND-420.

Explore the full profile